Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapyStefania Gori, Guido Arcaro, Alessandro Inno et al.|Critical Reviews in Oncology/Hematology|2019Cited by 164
Entrectinib: a potent new TRK, ROS1, and ALK inhibitorChristian Rolfo, Luis E. Raez, Rossana Ruiz et al.|Expert Opinion on Investigational Drugs|2015Cited by 153
<i>BRAF<sup>V600E</sup></i> mutation and p27<sup>kip1</sup> expression in papillary carcinomas of the thyroid ≤1 cm and their paired lymph node metastasesVito Rodolico, Carla Giordano, Daniela Cabibi et al.|Cancer|2007Cited by 78
Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyondDaniela Di Lisi, Giuseppina Novo, Rosalinda Madonna et al.|International Journal of Cardiology|2016Cited by 73
The role of Aurora-A inhibitors in cancer therapyValentina Agnese, Antonio Russo|Annals of Oncology|2007Cited by 70